文献速递神经肿瘤脊柱脊髓外科

高级别脊柱脑膜瘤患者的生存分析:基于美国国家癌症数据库的研究

Survival in Patients with High-Grade Spinal Meningioma: An Analysis of the National Cancer Database.
PubMed 文献 · World Neurosurg · 2019-06-14

本研究利用美国国家癌症数据库(NCDB)回顾性分析了2004至2015年间287例经组织病理学确诊的WHO II级或III级脊柱脑膜瘤患者,评估其基线人口学特征、生存差异及围手术期结局。多因素分析未发现WHO II级与III级患者在总生存期上存在显著差异(HR=2.01,95%CI 0.89-4.52,P=0.09),但III级患者显示出生存更差的趋势。

要点

  • WHO II级与III级脊柱脑膜瘤患者的总生存期无显著差异,但III级有更差趋势。
  • 术后30天非计划再入院率为4.2%,90天内死亡2例。
  • III级病变患者从诊断到治疗的时间最短,平均为10.8天。

核心结论

  • WHO II级与III级脊柱脑膜瘤患者的总生存期无显著差异(HR=2.01,95%CI 0.89-4.52,P=0.09),但III级病变存在生存更差的趋势。

研究设计与样本

  • 回顾性队列研究,查询美国国家癌症数据库(NCDB)2004至2015年数据,纳入287例经组织病理学确诊的WHO II级或III级脊柱脑膜瘤患者。

主要发现

  • 患者平均年龄56.4岁,女性占70%(n=201),45.3%(n=130)在学术/研究机构接受治疗。
  • III级病变患者从诊断到治疗的平均时间最短,为10.8天。
  • 术后30天非计划再入院率为4.2%(n=12),90天内死亡2例。
  • 多因素分析显示WHO II级与III级病变的生存无显著差异(HR=2.01,95%CI 0.89-4.52,P=0.09)。

临床怎么用

  • 对于高级别脊柱脑膜瘤,应关注术后30天再入院风险及90天内死亡风险。
  • III级病变患者虽无统计学显著生存差异,但临床仍需警惕其潜在更差预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report baseline demographics and examine for differences in survival for patients with World Health Organization (WHO) grade II and III spinal meningioma. METHODS: The National Cancer Database was queried for patients diagnosed with WHO grade II or grade III spinal meningioma between 2004 and 2015. Cases with histopathological confirmation were included. Descriptive statistics were calculated and stratified by tumor type. Facility type, 30-day readmission, and 90-day mortality were also examined. Crude and adjusted Cox proportional hazards regression models were used to evaluate for differences in survival. RESULTS: A total of 287 patients with WHO grade II or grade III spinal meningioma (white, n = 237; black, n = 32; Asian and Pacific Islander, n = 11; unknown race, n = 7) were identified. The mean patient age was 56.4 years, and the majority were female (70%; n = 201). Almost one-half of the patients were treated in an academic/research program (45.3%; n = 130,). Those with WHO grade III lesions received the earliest treatment, at a mean of 10.8 days following diagnosis. The proportion of patients with unplanned 30-day readmission following surgery was 4.2% (n = 12). Two patients died within 90 days of surgery. Multivariable analysis demonstrated no differences in survival for patients with WHO grade II or grade III lesions (hazard ratio, 2.01; 95% confidence interval, 0.89-4.52; P = 0.09). CONCLUSIONS: No difference in overall survival was identified between patients with WHO grade II or III spinal meningioma, although a trend was seen toward worse survival for patients with WHO grade III lesions.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wright JM, Wright CH, Cioffi G, et al. Survival in Patients with High-Grade Spinal Meningioma: An Analysis of the National Cancer Database. World Neurosurg. 2019. PMID: 31203074. doi:10.1016/j.wneu.2019.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。